Search | IOVS | ARVO Journals

Showing 1 – 20 of 51

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

Laterally Spreading AAV.SPR-hRS1 Vector for Treatment of XLRS

Linda Couto; Dana Elmore; James Peterson; Hangning Zhang; Laurence Ocelli; Ryan Boyd; Lauren Knupp; Sanford Boye; Shannon Boye

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2825 – A0341. doi:

ARVO Annual Meeting Abstract June 2022

Improving retinal vascular endothelial cell tropism through rational rAAV capsid design.

Ramesh Periasamy; Dwani D Patel; Sanford L Boye; Shannon E Boye; Daniel M Lipinski

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):66 – A0039. doi:

ARVO Annual Meeting Abstract June 2022

Investigating the functional role of β4B-tubulin in vision

Urikhan Sanzhaeva; Shannon E. Boye; Visvanathan Ramamurthy

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1932 – F0350. doi:

ARVO Annual Meeting Abstract June 2021

Four-year follow up of intraocular pressure (IOP) control in a canine model of open-angle glaucoma (OAG) treated with adeno-associated virus (AAV)-mediated modification of gene expression within the aqueous humor outflow pathways (AHOP)

Andras M Komaromy; Christine Harman; Kristin Koehl; Amanda Anderson; Sanford L Boye; Juan Pedro Steibel; Leandro Teixeira; Carol B Toris; Sayoko E Moroi; Shannon E Boye

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2783. doi:

ARVO Annual Meeting Abstract June 2021

Development of rAAV capsid mutant vectors with improved tropism for retinal vascular endothelial.

Ramesh Periasamy; Dwani Patel; Shannon E Boye; Sanford L Boye; Daniel M Lipinski

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1468. doi:

ARVO Annual Meeting Abstract June 2021

Gene therapy and gene-editing approaches to treat vision loss in a murine model of Acadian Usher syndrome

Katelyn N Robillard; Bhagwat V Alapure; Sanford L Boye; Shannon E Boye; Nicolas G Bazan; Jennifer J Lentz

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1184. doi:

ARVO Annual Meeting Abstract June 2020

Genetic strategies to treat vision loss in a murine model of Acadian Usher syndrome

Katelyn N Robillard; Sanford Boye; Shannon Boye; Nicolas G Bazan; Jennifer J Lentz

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2443. doi:

ARVO Annual Meeting Abstract June 2020

Targeting Retinal Vascular Endothelial cells using rAAV Capsid Mutant Vectors

Ramesh Periasamy; Dwani Patel; Benyapa Khowpinitchai; Shannon Boye; Sanford Boye; Daniel M Lipinski

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4480. doi:

ARVO Annual Meeting Abstract July 2019

Highly Efficient Foveal Cone Transduction by AAV44.9 and AAV2(4pMutΔHS) Mediated by Lateral Spread Following Extrafoveal Subretinal Injection

Ryan F. Boyd; Joshua T Bartoe; Thomas S Vihtelic; James J Peterson; Hangning Zhang; Sanford L Boye; Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1330. doi:

ARVO Annual Meeting Abstract July 2019

Long-term stable intraocular pressure (IOP) control and optic nerve head (ONH) preservation following AAV-mediated ocular gene therapy in a canine model of ADAMTS10 -open-angle glaucoma (OAG)

Andras M Komaromy; Kristin L Koehl; Christine Harman; Sanford L Boye; Juan P. Steibel; Leandro B C Teixeira; Carol B Toris; Sayoko Eileen Moroi; Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6470. doi:

ARVO Annual Meeting Abstract July 2018

Investigating tolerability of subretinally delivered dual AAV-MYO7A vectors in non-human primate (NHP)

Kaitlyn Calabro; Sanford L Boye; Kevin Mccullough; Diego Fajardo; W Clay Smith; Christianne E Strang; Douglas C. Witherspoon; Dibyendu Chakraborty; Paul D Gamlin; Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4535. doi:

ARVO Annual Meeting Abstract July 2018

AAV 44.9- a novel capsid that efficiently transduces photoreceptors and retinal pigment epithelium

Shreyasi Choudhury; Russell Mellen; Kevin Mccullough; James Peterson; Diego Fajardo; John Chiorini; Sanford L Boye; Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4536. doi:

ARVO Annual Meeting Abstract July 2018

Subfoveal Injections in Non-Human Primates: Safety and Efficacy Following Administration of a Photoreceptor-Targeted AAV5

Ryan F. Boyd; Joshua T. Bartoe; Thomas S Vihtelic; Sanford L Boye; Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5662. doi:

ARVO Annual Meeting Abstract July 2018

An AAV-CRISPR/Cas9 gene editing approach for GUCY2D -associated cone rod dystrophy (CORD6)

Kevin Mccullough; Sanford L Boye; Diego Fajardo; Christianne E Strang; Douglas C. Witherspoon; Sebastian Gloskowski; Abhishek Dass; Paul D Gamlin; Morgan Maeder; Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):6020. doi:

ARVO Annual Meeting Abstract July 2018

Development of a drug-regulated, broad-spectrum neuroprotective gene therapy for retinal degeneration

John D Ash; Casey Keuthan; Aisha Imam; Sanford L Boye; Shannon Elizabeth Boye; Clayton Santiago

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3961. doi:

ARVO Annual Meeting Abstract June 2017

AAV5 made by rHSV complementation displays increased retinal transduction relative to AAV5 made by plasmid transfection.

Kevin Tyler Mccullough; Laura Adamson-Small; James Peterson; Sanford Boye; Nathalie Clément; Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4084. doi:

ARVO Annual Meeting Abstract June 2017

Directed Evolution of Enhanced AAV Capsid Variants Following Intravitreal Injection in Macaque

Sanford L Boye; Shreyasi Choudhury; Damien Marsic; Christianne E Strang; John J Alexander; C. Douglas Witherspoon; Sergei Zolotukhin; Paul D Gamlin; Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4087. doi:

ARVO Annual Meeting Abstract June 2017

Investigating the utility of mice as a model for developing clinically relevant dual AAV vectors to treat USH1B

Kaitlyn Calabro; Sanford Boye; Kevin Tyler Mccullough; Shreyasi Choudhury; Paul D Gamlin; Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4098. doi:

ARVO Annual Meeting Abstract June 2017

Optimization of transgene expression in the trabecular meshwork (TM) by comparing capsid mutant AAV2 vectors

Christine Harman; Kristin Koehl; Annie Oh; Vince A Chiodo; Sanford L Boye; William W Hauswirth; Shannon Elizabeth Boye; Andras M Komaromy

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4611. doi:

ARVO Annual Meeting Abstract June 2017

Novel AAV variants isolated by directed evolution in primate display enhanced retinal transduction following intravitreal injection

Shreyasi Choudhury; Damien Marsic; James Peterson; Diego Fajardo; Antonette Bennett; Paul D Gamlin; Mavis Agbandje-McKenna; Sergei Zolotukhin; Sanford L Boye; Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4507. doi:

1 2 3

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Laterally Spreading AAV.SPR-hRS1 Vector for Treatment of XLRS

Improving retinal vascular endothelial cell tropism through rational rAAV capsid design.

Investigating the functional role of β4B-tubulin in vision

Four-year follow up of intraocular pressure (IOP) control in a canine model of open-angle glaucoma (OAG) treated with adeno-associated virus (AAV)-mediated modification of gene expression within the aqueous humor outflow pathways (AHOP)

Development of rAAV capsid mutant vectors with improved tropism for retinal vascular endothelial.

Gene therapy and gene-editing approaches to treat vision loss in a murine model of Acadian Usher syndrome

Genetic strategies to treat vision loss in a murine model of Acadian Usher syndrome

Targeting Retinal Vascular Endothelial cells using rAAV Capsid Mutant Vectors

Highly Efficient Foveal Cone Transduction by AAV44.9 and AAV2(4pMutΔHS) Mediated by Lateral Spread Following Extrafoveal Subretinal Injection

Long-term stable intraocular pressure (IOP) control and optic nerve head (ONH) preservation following AAV-mediated ocular gene therapy in a canine model of ADAMTS10 -open-angle glaucoma (OAG)

Investigating tolerability of subretinally delivered dual AAV-MYO7A vectors in non-human primate (NHP)

AAV 44.9- a novel capsid that efficiently transduces photoreceptors and retinal pigment epithelium

Subfoveal Injections in Non-Human Primates: Safety and Efficacy Following Administration of a Photoreceptor-Targeted AAV5

An AAV-CRISPR/Cas9 gene editing approach for GUCY2D -associated cone rod dystrophy (CORD6)

Development of a drug-regulated, broad-spectrum neuroprotective gene therapy for retinal degeneration

AAV5 made by rHSV complementation displays increased retinal transduction relative to AAV5 made by plasmid transfection.

Directed Evolution of Enhanced AAV Capsid Variants Following Intravitreal Injection in Macaque

Investigating the utility of mice as a model for developing clinically relevant dual AAV vectors to treat USH1B

Optimization of transgene expression in the trabecular meshwork (TM) by comparing capsid mutant AAV2 vectors

Novel AAV variants isolated by directed evolution in primate display enhanced retinal transduction following intravitreal injection

To View More...

You must be signed into an individual account to use this feature.